The tumor suppressor p53 is often inactivated via its interaction with endogenous inhibitors mouse double minute 4 homolog (MDM4 or MDMX) or mouse double minute 2 homolog (MDM2), which are frequently overexpressed in patients with acute myeloid leukemia (AML) and other cancers. Pharmacological disruption of both of these interactions has long been sought after as an attractive strategy to fully restore p53-dependent tumor suppressor activity in cancers with wild-type p53. Selective targeting of this pathway has thus far been limited to MDM2-only small-molecule inhibitors, which lack affinity for MDMX. We demonstrate that dual MDMX/MDM2 inhibition with a stapled -helical peptide (ALRN-6924), which has recently entered phase I clinical testing, produces marked antileukemic effects. ALRN-6924 robustly activates p53-dependent transcription at the single-cell and single-molecule levels and exhibits biochemical and molecular biological on-target activity in leukemia cells in vitro and in vivo. Dual MDMX/MDM2 inhibition by ALRN-6924 inhibits cellular proliferation by inducing cell cycle arrest and apoptosis in cell lines and primary AML patient cells, including leukemic stem cell-enriched populations, and disrupts functional clonogenic and serial replating capacity. Furthermore, ALRN-6924 markedly improves survival in AML xenograft models. Our study provides mechanistic insight to support further testing of ALRN-6924 as a therapeutic approach in AML and other cancers with wild-type p53.
INTRODUCTION
The p53 protein is the most frequently inactivated tumor suppressor in human cancers (1) (2) (3) (4) . Its numerous functions include the protection of cells from genomic instability and prevention of progression and dissemination of aberrant cells by responding to cellular stress signals, resulting in a transcriptional response that triggers cell cycle arrest, DNA repair, senescence, and/or apoptosis pathways (5, 6) . In the hematopoietic system, p53 protects hematopoietic stem cells (HSCs) against DNA damage by promoting quiescence and inhibiting selfrenewal (7) (8) (9) (10) (11) (12) . Loss of p53 function in stem and myeloid progenitor cells promotes leukemia initiation by enabling aberrant self-renewal (13) . In de novo acute myeloid leukemia (AML), TP53 mutations are rare, occurring in less than 10% of patients (14) (15) (16) (17) (18) . Although in some specific subsets of AML TP53 mutations are more frequent [for example, in up to 80% in patients with complex cytogenetics (19) ], p53 inactivation more often results from the overexpression of its endogenous inhibitors MDMX or MDM2, which frequently occurs in p53 wild-type (WT) AML (20) (21) (22) (23) (24) (25) (26) . It was recently reported that MDMX protein and mRNA are overexpressed in up to 92% of AML cases (27) . MDM2 is an E3 ubiquitin ligase that inhibits p53 by targeting it for degradation, whereas MDMX inhibits its transactivation activity and promotes MDM2 activity via direct protein-protein interactions (3, (28) (29) (30) (31) (32) (33) (34) (35) . Seminal work by several groups demonstrated that MDMX and MDM2 play indispensable and nonoverlapping roles in suppressing the normal function of p53 and that dual inhibition of MDMX and MDM2 is essential to fully unleash dormant p53 (36) (37) (38) (39) (40) (41) (42) .
Given their critical role as negative regulators of p53 tumor suppressor functions, pharmacological disruption of MDMX/MDM2/p53 interactions offers a means to restore p53 activity in p53 WT cancers that might be MDMX-reliant, such as AML. However, efforts to develop small-molecule dual MDMX/MDM2 inhibitors have been largely unsuccessful. The cis-imidazoline compound Nutlin-3 was one of the first antagonists of MDM2-p53 binding shown to restore p53 tumor suppressor function in p53 WT preclinical cancer models; however, due to poor bioavailability, it never advanced to the clinical trial phase (43) . Optimized small-molecule inhibitors of MDM2 are currently undergoing clinical testing, with the cis-imidazoline derivatives RG7112 and RG7388 (idasanutlin) being the most advanced, and have generated partially encouraging results (44) . However, limitations of these compounds include their lack of affinity for MDMX, which has been reported to antagonize the effects of MDM2 inhibition in tumor cells, as well as dose-limiting toxicities in patients (25, (45) (46) (47) (48) (49) (50) . More recently, -helical p53-stapled peptide prototypes have shown promise, demonstrating the feasibility of targeting both MDMX and MDM2 (49, (51) (52) (53) (54) . ALRN-6924 is an optimized -helical p53-stapled peptide and a dual MDMX/MDM2 inhibitor currently in phase I clinical testing in solid tumors and lymphomas, with thus far excellent tolerability and some promising signs of antitumor activity (55) . However, its molecular, cellular, and biochemical mechanisms of action, as well as its therapeutic potential in AML, have yet to be determined.
Here, we demonstrate that MDMX is considerably overexpressed in AML, including in leukemia stem cell-enriched populations, in comparison to age-matched healthy controls. Thus, targeting MDMX with a dual MDMX/MDM2 inhibitor is an attractive therapeutic strategy in AML. We found that ALRN-6924 activates p53-dependent tran scription at the single-cell and singlemolecule levels and displays robust biochemical and molecular biological on-target activity in leukemia cells. ALRN-6924-mediated dual MDMX/MDM2 inhibition results in genome-wide activation of p53-dependent transcriptional networks. It induces cell cycle arrest and apoptosis pathways in cell lines and primary AML patient cells, including in leukemic stem cell (LSC)-enriched populations. It also disrupts key functional properties, including clonogenic and serial replating capacity of leukemia-initiating cells, with remarkably better activity than RG7388 (idasanutlin), an MDM2-only small-molecule inhibitor, which is currently in phase 3 trials in myelodysplastic syndrome (MDS) and AML. Furthermore, ALRN-6924 inhibits leukemia pathogenesis and increases survival in AML xenograft models in vivo. Our study offers insight into the effects of dual MDMX/MDM2 inhibition using a stapled peptide therapeutic in leukemia and provides a rationale for further development and clinical testing of ALRN-6924 as a therapeutic approach in cancers with WT p53.
RESULTS

MDMX is highly expressed in AML
MDMX overexpression has been reported in a number of human cancers, including glioma, soft tissue sarcoma, melanoma, retinoblastoma, breast cancers, and hematological malignancies (24, 27, (56) (57) (58) (59) (60) (61) . To compare MDMX expression in patients with different cancer types, we evaluated published gene expression data sets available in The Cancer Genome Atlas (TCGA). Notably, primary cells from patients with AML have very high expression of MDMX compared to most other tumor types (Fig. 1A) . Tumor cell lines derived from hematological malignancies also have high expression of MDMX compared to cell lines of other tumor types ( fig. S1A ). Alternative splicing of MDMX results in the expression of a shorter nonfunctional isoform, MDMX-S, lacking exon 6, previously reported to attenuate full-length (FL) MDMX protein expression (62) . To more carefully examine which Avg K i (nM)
1.3 7.1 Fig. 1 . MDMX is targetable in acute myeloid leukemia using an -helical stapled peptide (ALRN-6924). (A) mRNA expression analysis of MDMX in human cancers using The Cancer Genome Atlas (TCGA) data sets and (B) MDMX and MDM2 mRNA expression in hematopoietic stem (HSC) and granulocyte-monocytic progenitor-enriched (GMP) cells from acute myeloid leukemia (AML) patients (n = 14) and healthy controls (n = 6) (data shown as mean ± SD, where **P < 0.01, ***P < 0.001; n.s., not significant). (C) Fluorescence polarization (mP) of a fixed concentration of ALRN-3618 was measured in the presence of varying concentrations (log M) of mouse double minute 2 homolog (MDM2) and MDMX (top panels) (n = 2). Graphs display varying concentrations of ALRN-6924 used to displace ALRN-3618 at its EC 80 from each target protein (bottom panels). (D) IC 50 and K i values (n = 2) for each target protein, as determined from a nonlinear four-parameter curve obtained from plotting fluorescence polarization versus drug concentration in (C) (bottom). (E) Sensorgrams for the binding of ALRN-6924 (blue) and RG7388 (red) to surfaces with immobilized MDM2 (top) and MDMX (bottom) (n = 2). (F) Enzyme-linked immunosorbent assay demonstrating the expression of human p21 protein (left) (21 hours after treatment with ALRN-6924) and cellular caspase activity (right) (48 hours after treatment with ALRN-6924) determined using Caspase-Glo 3/7 assay reagent in SJASA-1 cells (n = 2; data shown as mean ± SD). ACC, adrenocortical carcinoma; DLBC, diffuse large B cell lymphoma; PCPG, pheochromocytoma and paraganglioma; RCC, renal cell carcinoma. (63) . Total MDMX expression was significantly higher in leukemic stem (P < 0.0001) and progenitor cells (P = 0.0013) compared to healthy controls; however, this was not the case for MDM2 (Fig. 1B) . These results demonstrate that FL MDMX is over expressed in AML, including in leukemia stem cells, compared to MDM2, and thus provide a strong rationale for the evaluation of MDMX-targeting compounds in this devastating disease.
ALRN-6924 binds with high affinity to both human MDMX and MDM2 pDI is a prototype linear -helical peptide identified by phage display that shows nanomolar binding affinity to MDMX and MDM2 (64, 65) . Unlike ALRN-6924, pDI lacks a chemical linker ("staple"), and it is not cell-permeable. The binding kinetics of ALRN-6924 were measured in a competitive binding assay using a modified pDI peptide (ALRN-3618) synthesized with a fluorescent 5-FAM moiety (5-carboxyfluorescein) appended via a -alanine spacer to its N terminus (5-FAM--alanine-pDI) as a binding probe. ALRN-3618 bound with high affinity to purified MDM2 [dissociation constant (K d ) = 33.6 nM) and MDMX (K d = 83 nM), demonstrating dual target binding for this linear peptide (Fig. 1C, upper panels) . Varying concentrations of ALRN-6924 were used to displace ALRN-3618 at its EC 80 from each target protein. ALRN-6924 displaced ALRN-3618 at its EC 80 for the p53-binding site on MDM2, suggesting that they bind to the same site on MDM2 (Fig. 1C, left lower panel) . ALRN-6924 displaced ALRN-3618 at its EC 80 for the p53-binding site on MDM2 and MDMX, suggesting that they bind to the same site on MDM2/X (Fig. 1C , left and right lower panels, respectively). The results indicate that ALRN-6924 binds with high affinity to both MDMX and MDM2 and are summarized in Fig. 1D . Notably, ALRN-6924 demonstrated superior binding kinetics versus the smallmolecule Nutlin derivative RG7388 (Fig. 1E) . In binding assays using immobilized MDMX-and MDM2-coated surfaces, ALRN-6924 binding to MDM2 was sustained during wash-off with a t 1/2 = 85 min (Fig. 1E, upper panel) . In contrast, RG7388 washed off from MDM2-coated surfaces with a shorter half-life (t 1/2 = 2 to 3 min). ALRN-6924 demonstrated specific binding to MDMX with a wash-off t 1/2 = 5 min, whereas RG7388 did not bind to MDMX at all (Fig. 1E, lower  panel) . ALRN-6924 bound to MDMX and MDM2 (K d = 57 and 10.9 nM, respectively) (table S1) with binding kinetics superior to those of endogenous p53 (K d = 480 and 770 nM, respectively) (66) , an important characteristic of ALRN-6924 that facilitates the disruption of native p53-MDMX/MDM2 complexes.
ALRN-6924 treatment of SJSA-1 cells, which have an intact p53 signaling pathway and were previously reported to be sensitive to dual MDMX/MDM2 inhibition (51) , resulted in a concentrationdependent increase in p21 protein and in caspase-3/7 activityindicating that the p53 pathway had been activated (Fig. 1F) . To test its efficacy in hematological malignancies, we treated a variety of leukemia cell lines with ALRN-6924 and found that it exhibited potent activity against all five cell lines with WT p53 in the cytotoxicity assay (table S2) . Moreover, ALRN-6924 also showed increased cytotoxic activity against one cell line (MOLT16) harboring a heterozygous TP53 mutation (R158H), which has been described as a loss-of-function mutation (http://p53.iarc.fr), but still carries one remaining TP53 WT allele. Thus, ALRN-6924 activated p53-mediated pathways of cell cycle arrest (via p21 up-regulation) and/or apoptosis (via cellular caspase activation) in all tested WT p53 tumor cell lines of hematological origin.
ALRN-6924 rapidly increases transcriptional bursting dynamics from the CDKN1A (p21) gene locus The majority of mammalian genes are transcribed dynamically over short periods of time, defined as a series of transcriptional bursts (67, 68) . Transcription dynamics can be regulated by changes in burst frequency, duration, and intensity. To better understand how ALRN-6924 affects transcriptional dynamics of p53 target genes, we quantified the expression of the CDKN1A gene using the MS2 system in live cells (69) . Briefly, we used the clustered regularly interspaced short palindromic repeats-CRISPR associated protein 9 (CRISPR-Cas9) system (70) to knock-in 24 MS2 stem-loop (MS2-SL) repeats into the 3′ untranslated region (3′UTR) of the endogenous CDKN1A gene locus in human osteosarcoma (U2OS) cells, which we found to be amenable to CRISPR-Cas9 manipulation, RNA-fluorescence in situ hybridization (RNA-FISH), and live cell imaging ( Fig. 2A) . This genetically engineered cell line model allowed us to directly measure actual transcriptional bursting dynamics from a canonical p53 target gene locus in response to p53 activation (as opposed to measurements of RNA levels, which are influenced by many factors besides transcription) at the single-molecule (nascent RNAs synthesized at the CDKN1A locus) and single-cell levels. Single-molecule RNA-FISH confirmed that the cell line contained an insertion into a single allele of the p21 gene ( fig. S2 ). This modified cell line also stably expressed a green fluorescent protein (GFP)-tagged MS2 capsid protein (MCP-GFP), which binds RNA harboring the MS2-SL ( Fig. 2A) (69) . Live cell fluorescence microscopy was used to visualize nascent transcription sites (TSs) containing a single bright MCP-GFP spot bound to MS2-SL-containing RNA on the p21 gene locus (Fig. 2B, top panel) . The fluorescence intensity of the MCP-GFP spot is related to the amount of nascent transcripts originating from the p21 gene.
At the single-cell level in untreated conditions, transcription of the p21 gene infrequently switches between ON and OFF states over time (Fig. 2B ). Quantification showed multiple bursts of transcription during the 10-hour imaging window ( Fig. 2B and movie S1), with no major changes before and after the medium replacement. Next, we examined the effect of ALRN-6924 on p21 transcriptional dynamics. Addition of ALRN-6924 resulted in longer and more intense transcriptional bursts compared to untreated cells (Fig. 2 , C versus B, and movie S2). To rule out potential effects related to single-cell heterogeneity, we calculated the proportion of cells in a population containing an active TS over time. In an untreated population, 16% of the cells contained an actively transcribing p21 gene at any given time (Fig. 2D , top panel). The proportion of cells harboring an active TS steadily increased to ~44% at 4 hours after the addition of ALRN-6924 (Fig. 2D , top versus bottom panel). Therefore, ALRN-6924 increased the duration and/or frequency of transcriptional bursting at the p21 gene. To further quantitate the effects of ALRN-6924 on rates of p21 transcription, we plotted the cumulative MS2 signal over time (Fig. 2E) . Notably, we observed a considerable difference in the rate of p21 transcription between treated and untreated cells within 2 hours after the addition of ALRN-6924 (compare slopes of ALRN-6924 versus untreated; Fig. 2E ). Furthermore, an increased rate of transcription was maintained throughout the 10-hour treatment window, indicating that ALRN-6924 triggered a durable transcrip tional response. Collectively, these data suggest that ALRN-6924 rapidly penetrates cellular membranes and triggers on-target downstream p53-dependent tran scriptional programs.
Dual inhibition of MDMX and MDM2 with ALRN-6924 activates the p53 pathway in AML
To directly measure ALRN-6924's cell permeability, we treated AML cells with increasing concentrations of FAM-tagged ALRN-6924 and then analyzed them by flow cytometry and high-resolution fluorescence microscopy. Intracellular ALRN-6924, which was detectable both in the cytoplasm and nucleus, as well as an increase in p53 protein, was observed within 3 hours of treatment (Fig. 3, A and B) . We then analyzed its ability to disrupt preformed p53-MDM2 and p53-MDMX-FL complexes [using an MDMX-FLspecific antibody (Millipore 8C6)] by co immunoprecipitation and immunoblotting in AML cells treated with ALRN-6924 or vehicle. Consistent with in vitro biochemical assays, we found that ALRN-6924 disrupted endogenous p53-MDM2 and p53-MDMX-FL complexes in AML cells (Fig. 3C , left and right panels, respectively, and fig. S3A ). Next, we treated patient-derived primary AML cells and AML cell lines expressing WT p53 with increasing concentrations of ALRN-6924 and analyzed cellular lysates for evidence of p53 pathway activation. ALRN-6924 stabilized p53 and up-regulated its downstream targets p21 and MDM2 in p53 WT cells in a dose-dependent manner, but not in p53 null AML cells (Fig. 3D  and fig. S3 , B and C). MDMX-FL was slightly down-regulated in response to ALRN-6924 ( fig. S3D ). Furthermore, analysis by RNA sequencing showed that ALRN-6924 triggered differential changes in gene expression compared to vehicle-treated MOLM13 cells within 6 hours after treatment (Fig. 3E) . We found 954 differentially expressed genes in response to ALRN-6924, and gene set enrichment analysis (GSEA) showed a consistent and reproducible enrichment of p53-regulated gene expression signatures (Fig. 3F) . Notably, the top upregulated pathways in ALRN-6924-treated cells included genes involved in p53 signaling, cell cycle arrest, and apoptosis induction ( Fig. 3F and fig. S3E ). Fig. 4A and fig. S4D ). ALRN-6924 inhibited cellular proliferation measured by trypan blue exclusion in a dose-and time-dependent manner (Fig. 4, A and B) .
Only one p53 WT cell line, OCI/AML3, was less sensitive to treatment with ALRN-6924 in suspension culture; notably, this cell line had lower MDMX-FL/MDMX-S and MDMX-FL/MDM2 ratios than the other cell lines tested (Fig. 4, A and B, and  fig. S4, A and B) . Notably, ALRN-6924 had no effect on cell proliferation in HL60 (p53 null) or Kasumi-1 (p53 R248Q mutant) AML cell lines ( fig. S4,  D and E) .
To more carefully dissect the mode of ALRN-6924-dependent growth inhibition, we analyzed its effects on cell cycle and apoptosis by propidium iodide and annexin V staining, respectively. ALRN-6924 induced cell cycle arrest in all p53 WT AML cell lines ( fig. S4F) . Moreover, ALRN-6924 triggered a dose-dependent increase in ap optosis in all five AML cell lines tested; however, the two cell lines with lower expression of both MDMX and MDM2 (OCI-AML3, ML2) were consistently less responsive (Fig. 4C) . We did not observe a significant increase in apoptosis in p53 null (HL60) cells even at the range of doses that were cytotoxic in p53 WT cells, between 5 and 10 M (fig. S4E) (Fig. 4D) . Notably, ALRN-6924 exhibited greater inhibition of clonogenicity compared to RG7388 in all five AML cell lines.
To directly test the p53 dependency of ALRN-6924's effects, we generated two isogenic p53 short hairpin RNA (shRNA) knockdown cell lines derived from MOLM13 cells and assessed the effects of ALRN-6924 treatment on cell proliferation and apoptosis (Fig. 4E) . We found that ALRN-6924 inhibited cell growth and induced apoptosis in a completely p53-dependent manner (Fig. 4 , F and G).
ALRN-6924 displays robust antileukemic effects in primary patient-derived AML cells and AML xenograft models
To study the antileukemic effects of ALRN-6924 in p53 WT primary AML cells, patient-derived peripheral blood mononuclear cells (PBMCs) were treated in liquid culture with increasing concentrations of ALRN-6924. Cell viability was inhibited (compared to vehicle-treated cells) in a dose-and time-dependent manner in all samples tested (Fig. 5A) . ALRN-6924 inhibited CFC of primary AML PBMCs (n = 4) compared to healthy controls (n = 3), demonstrating a therapeutic window (Fig. 5B) . Next, we treated primary AML patients' bone marrow (BM) cells (n = 3) and BM cells from healthy donors (n = 3) in suspension culture with a cytotoxic dose of ALRN-6924 and analyzed its effects on cell viability and apoptosis in LSC-enriched compartments (CD34 + CD38 − ). We observed a significant (P = 9.38 × 10 −6 ) decrease in cell viability accompanied by increased apoptosis specifically in . Data are shown as the mean ± SD, and *P < 0.05, **P < 0.01, ***P < 0.001.
of 12
CD34 + CD38 − LSCs, but not in healthy donor CD34 + CD38
− cells (Fig. 5C ). Serial replating of CFCs is an important characteristic of the self-renewal properties inherent in LSCs in vitro. Therefore, we examined the ability of ALRN-6924 to inhibit the serial replating capacity of AML cells in comparison to RG7388, several previously characterized p53-stapled peptide prototypes, ATSP-7041 (the previously reported nonclinical MDMX/MDM2 stapled peptide), SAH-p53 (first p53-stapled peptide prototype), a selective stapled peptide targeting MDM2, and a selective nonclinical small-molecule MDMX inhibitor (54, 72) . The MDMX inhibitor NSC-207895 downregulated expression of MDMX in AML cells at the mRNA and protein levels ( fig. S4 , H and I). ALRN-6924 displayed increased potency over RG7388 and all other p53-stapled peptide prototypes tested in CFC and serial replating assays (Fig. 5D and  fig. S4G ), and in three of the five AML cell lines tested, ALRN-6924 completely abrogated serial replating capacity (Fig. 5D ). MDMX inhibition with NSC-207895 demonstrated similar potency to ALRN-6924 in serial replating assays, suggesting that MDMX plays an important functional role for AML cell serial replating capacity.
To test the efficacy of ALRN-6924 to inhibit leukemia initiation and disease progression in vivo, we used xenotransplantation models of AML. First, we transplanted NOD.Cg-Prkdc (fig. S5, A and B) . At day 7 after the start of treatment, we observed a dose-dependent decrease in human CD45 leukemic cells in the BM of ALRN-6924-treated animals ( fig. S5, A and B) . At this dosing regimen, the median survival was increased by 5.5 days compared to the control ( fig. S5C ). In the next set of experiments, MOLM13-transplanted animals were randomly divided into three additional groups treated with vehicle (I) Neutrophil and platelet counts assessed by Hemavet analysis of peripheral blood from mice (n = 10) on treatment with ALRN-6924 (20 mg/kg) TIW for 4 weeks. Data shown as the mean ± SD; *P < 0.05, **P < 0.01, ***P < 0.001.
was 23.3% in vehicle and 0.00557% in ALRN-6924-treated animals ( Fig. 5E ). Mice treated with ALRN-6924 showed a remarkable increase in overall survival compared to the vehicle-treated counterparts (Fig. 5F ). The median survival for groups 1, 2, and 3 was 34, 83, and 151 days, respectively (Fig. 5G) . Notably, 40% of mice in group 3 remained alive 300 days after treatment. In a second xenograft model, with ML2 cells, average median survival for vehicle-treated animals was 28.5 days. In contrast, animals treated with ALRN-6924 (20 mg/kg, IV) BIW and TIW had an average median survival of 38 and 72 days, respectively ( fig. S5, E and F) .
To assess the effects of ALRN-6924 on healthy hematopoietic cells, we treated non-tumor-bearing C57/BL6 mice with either vehicle or ALRN-6924 (20 mg/kg) TIW for 4 weeks. At the end of treatment, we analyzed the frequency of HSCs and progenitors and found no significant differences between control and ALRN-6924-treated animals (Fig. 5H) . ALRN-6924-treated animals appeared healthy throughout the treatment and did not show signs of thrombocytopenia and only a modest reduction in neutrophils [which remained within the normal range for this mouse strain (73)] (Fig. 5I) . Together, these data show that ALRN-6924 is a potent and selective inhibitor of primary human AML cells, including immature leukemia stem/progenitor cells, displays strong leukemia-inhibitory activity in vivo, and is well tolerated in mice.
ALRN-6924 selectively activates p53 in leukemia cells of an MDS/AML patient in vivo
We present a case of a 20-year-old female patient with germ-line deletion of one TP53 allele, who was suffering from metastatic breast cancer and developed high-risk MDS with excess of leukemic blasts [refractory anemia with excess blasts (RAEB), 15% blasts, with complex karyotype]. The patient was refractory to conventional chemotherapy; however, cytogenetic analysis revealed that the leukemic blasts had retained a WT copy of TP53. Relative TP53 mRNA expression was fourfold lower in the patient's MDS/AML cells compared to healthy donor CD34 + cells, and MDMX-FL was the predominant isoform expressed (Fig. 6A) . To assess whether the patient could benefit from treatment with ALRN-6924, the patient's MDS/AML cells were treated in vitro with vehicle, 10 M RG7388, or 10 M ALRN-6924. ALRN-6924 inhibited cell proliferation and clonogenic capacity of the patient's MDS/AML cells (Fig. 6 , B and C) and showed a greater AML-inhibitory effect than RG7388 (Fig. 6B) .
Because of lack of other therapeutic options, the patient was treated with ALRN-6924 for compassionate use. The patient received treatment with ALRN-6924 at 3.1 mg/kg, IV, once weekly. On the first administration of ALRN-6924, peripheral blood samples were collected at different time intervals [before infusion, end of infusion (EOI), 3 hours after EOI, and 12 hours after EOI] to evaluate p53 and its downstream target, p21, protein in leukemic blasts [defined as having negative staining for lymphocyte markers and CD34 + CD38
− staining] by intracellular FACS staining ( fig. S6A) . Notably, p53 protein was rapidly induced in CD34 + leukemic blasts, but not in healthy lymphocytes, suggesting that ALRN-6924 had a selective effect on the leukemia cells (Fig. 6D) 
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of the p53 pathway upon ALRN-6924 treatment in vivo. To monitor the percentage of circulating CD34 + leukemic blasts over time, peripheral blood was collected before infusion and 24 hours after EOI in weeks 2 and 3 of the weekly treatment cycles. Consistent with the patient's pathological report (Fig. 6E) , we observed a rapid decrease in circulating CD34 + leukemic blasts from 5 to 7% initially to 1.5 to 2.5% within 12 hours, followed by a further decline to less than 1% in weeks 2 and 3 ( Fig. 6E and fig. S6, B and C) . At the time of initial treatment, the patient presented with grade 3 neutropenia, which gradually improved while on treatment with ALRN-6924 (Fig. 6F, right panel) . Furthermore, no grade 3 or 4 thrombocytopenia was observed while the patient remained on treatment (Fig. 6F, left panel) . Despite the observed positive response, the patient could not continue further therapy due to infectious complications from metastatic breast cancer. These data provide proof of principle that a p53-stapled peptide dual MDMX/MDM2 inhibitor (ALRN-6924) engages the p53 pathway and has on-target antileukemic effects in a patient receiving treatment for compassionate use.
DISCUSSION
MDMX and MDM2 are frequently overexpressed in human cancers and exhibit oncogenic activity when overexpressed in experimental animal models (74, 75) . Furthermore, they play indispensable and nonoverlapping roles in suppressing the normal function of p53 during embryonic development in genetic mouse models (36) (37) (38) (39) (40) (41) . Thus, dual inhibition of MDMX and MDM2 can provide a means for reactivating p53 across a broad range of tumors, including AML. ALRN-6924 is an -helical stapled peptide dual MDMX/MDM2 inhibitor currently being tested in clinical trials (NCT02264613 and NCT02909972). ALRN-6924 represents an example of transforming proof-of-concept stapled peptide prototypes (49, 51, 54) into a bona fide drug candidate. In clinical trials, ALRN-6924 has thus far demonstrated efficacy and safety, with no reported grade 3/4 thrombocytopenias, and grade 3/4 neutropenia reported in less than 5% of patients (55) . However, a clear understanding of its molecular and cellular mechanisms of action will provide the rigorous and mechanistic support to compel continued testing of ALRN-6924 in hematologic malignancies and other cancers expressing WT p53.
We report that the MDMX-FL isoform is overexpressed in AML in comparison to other cancers, including at the leukemic stem/progenitor cell level. Thus, MDMX appears to be a particularly relevant target in AML. We demonstrate the molecular and cellular biological effects of pharmacological dual inhibition of MDMX/MDM2 with a p53-stapled peptide in AML. ALRN-6924 rapidly penetrates cellular membranes and stabilizes p53 in AML cells. It binds with high affinity to both MDMX and MDM2, blocking their interaction with p53 in AML cells. ALRN-6924 displays on-target activity at the single-cell level, triggering rapid and sustained transcriptional activation of the p21 gene by increasing the duration and frequency of transcriptional bursting in live cells. Genome-wide, ALRN-6924 activates known p53 transcriptional networks that mediate its tumor suppressor function (76) . At the cellular level, ALRN-6924 is a potent inhibitor of leukemia cell proliferation, triggering p53-dependent cell cycle arrest and apoptosis in AML cell lines and primary human leukemia cells. Therefore, we conclude that ALRN-6924 exhibits rapid and sustained on-target intracellular activity in living cells.
Leukemia initiating cells (LICs) are largely quiescent cells that can escape conventional chemotherapy and can cause disease relapse after a period of latency (77) (78) (79) . LSCs rely on oncogenic signals that inactivate the p53 pathway, and reactivation of dormant p53 in LICs can be a selective strategy to eradicate LICs (80) (81) (82) (83) − BM cells of healthy donors. This is consistent with our finding that specifically MDMX is overexpressed in fractionated stem and progenitor cells of AML patients (in comparison to stem/progenitor cells of agematched healthy controls), whereas MDM2 is not. In vivo, ALRN-6924 considerably increased overall survival of experimental animals in AML xenotransplantation mouse models and displayed robust intracellular biological activity in MDS/AML cells derived from a patient on treatment with ALRN-6924 for compassionate use. In this patient, we observed that the p53 pathway was selectively up-regulated in immature CD34 +
CD38
− MDS/AML cells, which resulted in a rapid and sustained reduction in circulating CD34
+ leukemic blasts after treatment with ALRN-6924. Our data demonstrate that ALRN-6924 is a biologically active compound exhibiting on-target and on-mechanism activity in AML cells in vitro and in vivo. Our study provides functional and molecular insight into the effects of dual MDMX/MDM2 inhibition using a stapled peptide in leukemia, and provides proof of concept to support continued testing of ALRN-6924 in WT p53 cancers with high expression of MDMX.
MATERIALS AND METHODS
Study design
The purpose of this study was to evaluate the molecular, biochemical, cellular, and in vivo effects of dual targeting of MDMX and MDM2 using an -helical stapled peptide (ALRN-6924) in AML. In vitro cellular studies were carried out using AML cell lines, primary AML cells, or healthy donor cells treated with the testing compound (ALRN-6924 or as otherwise specified) at concentrations ranging from 0.003 to 30 M. End points for viability and apoptosis analyses were selected on the basis of a time course ranging from 0 to 96 hours after addition of the drug to cells in culture. All cellular experiments were conducted in triplicates (technical replicates) and repeated independently at least three times unless otherwise noted. For additional details on experimental procedures, see the Supplementary Materials.
In vivo studies were performed to evaluate the effects of ALRN-6924 on leukemia initiation and progression, as well as the effects of different dosing concentrations and frequency of treatment. Xenotransplantation studies were carried out using 10 animals per group unless otherwise specified. Animals were transplanted via tail vein injections of 2.0 × 10 5 cells (unless otherwise specified), using either MOLM13 or ML2 human AML cells and randomly assigned to experimental groups as defined in the figure legends. All groups were dosed with vehicle (phosphate-buffered saline), ALRN-6924 (8 mg/kg), ALRN-6924 (12 mg/kg), or ALRN-6924 (20 mg/kg) at a frequency of twice per week for 10 weeks (unless otherwise noted) or three times per week for 5 weeks. The end point of these in vivo experiments was overall survival. All animals were sacrificed upon visual signs of disease progression. Exclusion criteria included unspecified death and body weight loss of more than 20%. All experiments were carried out as unblinded studies. For additional details on experimental procedures, see the Supplementary Materials.
Statistical analysis
All error bars indicate ± SD, representing at least three independent experiments, unless otherwise specified. Comparisons between two groups were analyzed using two-tailed (unpaired) Student's t tests unless otherwise specified. Multiple comparisons were analyzed using one-way analysis of variance (ANOVA) with Bonferroni correction in GraphPad Prism. A P value of 0.05 was considered to indicate statistical significance.
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